Jove
Visualize
Contact Us

Related Experiment Videos

Safety in clinical trials.

M A Wallander1

  • 1Department of Drug Surveillance, AB Hässle, Mölndal, Sweden.

Scandinavian Journal of Primary Health Care. Supplement
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Comprehensive adverse event analysis in drug development is crucial for patient safety. Mandatory collection and analysis of adverse events during clinical trials expedite the detection of drug-related threats, preventing long-term pharmaceutical risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development Of A Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (Pass) Programme Examining Rivaroxaban Use In Routine Clinical Practice.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.

Minerva cardioangiologica·2010
Same author

Geographical variation in adverse event reporting rates in clinical trials.

Pharmacoepidemiology and drug safety·2004
Same author

Health resource utilization and drug treatment pattern in a cohort of patients with a first episode of gastroesophageal reflux disease.

Pharmacoepidemiology and drug safety·2004
Same author

Ocular disorders in users of H2 antagonists and of omeprazole.

Pharmacoepidemiology and drug safety·2004
Same author

Gender and drug treatment as determinants of mortality in a cohort of heart failure patients.

European journal of epidemiology·2002
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacovigilance and patient safety.
  • Clinical trial methodology.
  • Drug safety surveillance.

Background:

  • Patient safety encompasses monitoring for subtle, late-onset syndromes alongside obvious threats like anaphylaxis.
  • Early detection of drug-induced adverse events is critical for patient well-being and regulatory compliance.

Purpose of the Study:

  • To emphasize the mandatory nature of collecting and analyzing adverse events throughout a drug's clinical trial program.
  • To highlight the risks associated with solely relying on investigator-reported adverse drug reactions.

Main Methods:

  • Systematic collection of all adverse events reported during the entire clinical trial program.
  • Analysis of collected adverse event data to identify potential drug-related threats.

Related Experiment Videos

  • Comparison of comprehensive adverse event reporting versus investigator-filtered adverse drug reactions.

    • Main Results:

    • Mandatory adverse event collection and analysis are essential for timely identification of potential drug-related harms.
    • Relying on investigator-reported adverse drug reactions may artificially lower incidence figures.
    • Filtering adverse events can obscure serious safety signals, posing long-term risks.

    Conclusions:

    • Comprehensive adverse event surveillance is indispensable for ensuring patient safety in drug development.
    • Pharmaceutical companies face long-term hazards by not mandating thorough adverse event collection and analysis.
    • Prioritizing complete adverse event data over filtered reports is vital for drug safety and industry integrity.